ABSTRACT. Benazepril (BP), an angiotensin convertive enzyme inhibitor, was administered orally once daily for 4 weeks to 31 dogs with mild to moderate (NYHA functional classes II and III) congestive heart failure caused from mitral insufficiency (MI). There were no significant changes in clinical signs, electrocardiogram findings, radiographical observations and plasma biochemical results in 11 dogs treated with placebo for 4 weeks. In 31 dogs treated with BP, appetite increased, and mean scores of heart failure signs, such as activity, exercise tolerance, cough and respiratory effort, were significantly improved. No dog displays signs suggesting systemic hypotension. One dog died suddenly on the 26th day of treatment with BP. This dog had good vigor and appetite till the evening before the death, and cough and exercise tolerance had been gradually improving. The heart rate and ECG parameters of BP treated dogs did not change significantly, but length of long axis of the heart decreased. In plasma biochemical tests, plasma urea nitrogen (UN) levels did not change significantly, and plasma creatinine (CRE) levels increased slightly within the normal ranges during BP trial. Two dogs had higher plasma UN levels with slightly higher plasma CRE levels, but had normal general condition and other biochemical results. Plasma ACE activity decreased to 57.3% of pre-treatment level at 4 weeks after BP treatment. It is concluded that BP monotherapy was efficacious at least in dogs with relatively low grade congestive heart failure caused by MI. -KEY WORDS: ACE inhibitor, benazepril, canine, congestive heart failure, mitral insufficiency.
classified into the modified New York Heart Association (NYHA) functional class I, and other 30 dogs were in class II or III [5] . When it was arbitrarily graded on a scale of I to VI [17] , the intensity of a heart murmur was in class II/ VI to IV/VI. Twenty-one dogs received BP-containing tablets for 4 weeks (BP trial). Ten dogs received placebo tablets for the first 4 weeks (placebo trial), and they were then enrolled into the group administered BP-containing tablets for the next 4 weeks. As the normal control of plasma ACE activity, clinically healthy 12 dogs were used.
Drug: BP (Fortecor, Ciba-Geigy Japan Ltd., Tokyo) was administered as tablets containing 5 mg of BP chloride. For placebo, an identical tablet without containing BP was used. Dogs received BP orally at a mean dose of 0.52 ± 0.22 mg/kg (range 0.27 to 1.19 mg/kg) once daily for 4 weeks without concomitant administration of other heart and vascular drugs, such as digitalis, diuretics and other vasodilators. Some additional drugs were used according to other diseases or signs, and these concomitant drugs used with BP are listed in Table 1 .
Procedures: The MI was diagnosed by a systolic cardiac murmur with auscultation, and abnormal valve action and blood regurgitation findings with 2 dimension and colordoppler echocardiography (EUB-165, Hitachi Medical Corp., Tokyo). Clinical check-up, radiography, electrocardiography (ECG, ECG 8820, Nihon Kohden Co., Ltd., Tokyo) and plasma biochemical tests (Dry-Chem 5,500V and 800V, Fuji Photo-Film Co., Ltd., Tokyo) were performed before and 1, 2, and 4 weeks after treatment. Plasma ACE activity was measured by Kasahara method [15] .
Angiotensin converting enzyme (ACE) inhibitors are potent vasodilator [6] . In humans and dogs, the effectiveness of ACE inhibitor treatment for hypertension and congestive heart failure has been well established [4, 6, 7, 10] , and trials indicate that the drugs improve the quality and duration of life [1] [2] [3] 14] . Many ACE inhibitors have been developed, and some are now in use in veterinary medicine. Benazepril (BP) is a new orally active and long acting ACE inhibitor without a sulfhydryl group [11, 12, 18] . The biological action of benazepril is considered to be exerted through benazeprilat, its active metabolite. Benazeprilat is excreted equally via liver and kidney [16] ; therefore BP can be used safely also in cases with renal dysfunction.
It is usually recommended that an ACE inhibitor is prescribed together with appropriate doses of digoxin and furosemide in dogs with congestive heart failure caused by dilated cardiomyopathy or mitral insufficiency (MI) [6, 10] . Because the use of an ACE inhibitor is usually recognized as a supportive therapy, there have been no clinical studies on monotherapy with an ACE inhibitor in canine congestive heart failure. The objective of the present study was to evaluate the clinical efficacy and safety of BP monotherapy in dogs with naturally acquired, relatively mild to moderate, congestive heart failure caused by MI.
MATERIALS AND METHODS

Dogs:
Experimental dogs are listed in Table 1 . All 31 dogs were outpatients of the Veterinary Hospital of Gifu University, and had naturally acquired MI. One dog was Data analysis: Clinical signs were evaluated with the score schemes (Table 2) . Statistical assessment of the mean scores before and after treatment was made with WilcoxonSigned ranks test. The data of laboratory tests and ECG were represented as mean ± standard deviation (SD), and the paired-Student's t-test was employed for the comparison of the data before and after treatment. Differences were considered as significant at a probability value of less than 0.05. Table 2 , there were no significant changes in clinical signs during placebo treatment. Appetite increased significantly during the BP trial, and mean scores of clinical signs of heart failure, such as activity, exercise tolerance, cough and respiratory effort, were significantly improved. Activity was improved in 5 dogs, but not changed in the other 26 dogs, those had almost normal activity before and throughout the trial. Exercise tolerance was normal throughout the trial in 14 dogs, was improved in 9 dogs, and did not change in 1 dog, but became transiently worse only in 1 dogs (No. 3657). The other 6 dogs did not take exercise. Cough was not observed in 10 dogs. It decreased in 14 dogs, increased in 2 dogs (Nos. 3668 and 4017), and did not change in 5 dogs. Respiratory effort was improved in 18 dogs, but became transiently worse in 2 dogs (Nos. 3698 and 3767). One or more signs of activity, exercise tolerance, cough and respiratory effort were improved in 24 of 31 dogs (77.4%), became to transiently worse in 4 dogs (12.9%), and did not change in 3 dogs (9.7%). One dog (No. 3668) vomited sometimes before and throughout the trial. Syncope, which had been observed in 2 dogs before the trial, disappeared in 1 dog (No. 3877), but not in another dog (No. 3841). Ascites was not observed in any dog. No dogs displayed signs suggesting systemic hypotension, such as depression, weakness, anorexia and unsteady gait. Body weight tended to decrease in the placebo trial, and increased in the BP trial. During the BP trial, one dog (No. 3728) died suddenly on the 26th treatment day. This dog had good vigor and appetite till the evening before the death, and cough and exercise tolerance had been gradually improving.
RESULTS
As shown in
As shown in Table 3 , heart rate and other ECG parameters did not change significantly both in the placebo and BP trials. There were no obvious changes in heart ventricular sizes on radiograms. However, as shown in Fig. 1 , mainstem bronchial compression was improved in 23 of 30 dogs (76.7%) from 1 or 2 weeks after start of BP treatment. On heart sizes ( Table 4) , length of long axis decreased significantly, but that of short axis did not change. Table 5 shows changes in plasma biochemical test results. There were no significant changes in laboratory test results during the placebo trial. Throughout the placebo trial, one dog (No. 3855) had a high plasma urea nitrogen (UN) level (78 mg/dl to 100 mg/dl) with slightly higher plasma creatinine (CRE, 1.4 to 1.7 mg/dl) and potassium (K, 4.5 mEq/l to 5.2 mEq/l) levels, but vigor, appetite and activity were almost normal. On the BP trial, plasma UN levels did not change significantly, but plasma CRE levels increased slightly. One dog (No. 3668) had a slightly higher plasma UN level (37 mg/dl) before BP treatment. In this dog, the UN level decreased to 23 mg/dl at 1 week, but increased to 60 mg/dl and 74 mg/dl at 2 weeks and 4 weeks after, respectively. However, this dogs showed good vigor and appetite, and had normal other biochemical test results with slightly higher plasma CRE levels (1.2 mg/dl to 1.6 mg/dl). In another dog (No. 3855) with higher plasma UN level (from 78 mg/dl to 100 mg/dl) during the placebo trial, the level decreased from 91 mg/dl at the beginning of BP trial to 40 mg/dl after 1 week, but increased to 109 mg/dl and 99 mg/dl at 2 weeks and 4 weeks, respectively. Plasma CRE levels were 1.4 mg/dl, 1.6 mg/dl, 1.7 mg/dl, and 1.2 mg/dl before and at 1, 2 and 4 weeks, respectively. Plasma sodium and chloride concentrations decreased slightly, but potassium level did not change significantly. As shown in Table 6 , mean plasma ACE activity was 5.3 ± 1.2 IU/L in 
DISCUSSION
Inhibition of ACE decreases arterial and ventricular filling pressures, and peripheral vascular resistance, and increases cardiac output [4, 13] . The rationale for using ACE inhibitors in congestive heart failure is the facilitation of ventricular emptying by reducing the peripheral vascular resistance [6] . The beneficial effect of BP on myocardial performance may be due to reduction of total peripheral resistance, which causes a decrease in the wall tension of the left ventricle and myocardial oxygen consumption [13, 15] . Most dogs used in the present study belonged to mild to moderate classes of NYHA heart failure classification (classes II and III). During BP treatment, clinical signs of heart failure were improved in 24 of 31 dogs (77.4%). Therefore, it is considered that BP monotherapy was efficacious at least in dogs with congestive heart failure of relatively low grade from MI. No significant changes were found in ECG data. However, decreases in mainstem bronchial compression and length of long axis of the heart in radiography, suggesting reduction of left atrial expanding, were observed. The treatment might induce vascular dilatation and decrease in venous blood return to the heart [8].
Adverse effects of ACE inhibitors include systemic hypotension, renal dysfunction, gastro-intestinal upsets (vomiting, diarrhea, and anorexia), and hyperkalemia. Azotemia may result from functional renal insufficiency in conjunction with ACE-inhibitor therapy [6] . In the present study, signs suggesting hypotension were not observed in any dog through trial. One dog (No. 3668) showed cough, vomit, and azotemia. In this dog, however, signs of cough and vomiting and slightly higher plasma UN and CRE levels had been observed already before treatment. Plasma UN levels decreased 1 week after, then increased from 2 weeks after BP treatment, but plasma CRE and K levels increased slightly, and activity and appetite of the dog were very good. Another azotemic dog (No. 3855) had a higher plasma UN level with slightly higher plasma CRE and K levels during the placebo trial, and these variables did not increase during the BP trial. These observations suggested pre-renal azotemia, and it was not clear that the azotemia was due to an adverse reaction of BP treatment. Plasma CRE level increased slightly during the BP trial. However, the levels were within the normal ranges, and those were not significant clinically. One dog (No. 3728) died suddenly on the 26th day of treatment with BP. In humans treated with ACE inhibitors, a relationship between decreased ventricular ectopy and sudden death, and reduced norepinephrine release has been suggested [6] . This dog had showed good vigor and appetite till the evening of the death. Cough, exercise tolerance and activity improved. The cause of the death was unknown, because the episode was during trip with his owner. From references [3] and our clinical experiences, sudden death might happen in dogs with MI.
The beneficial results presented in this study suggest that BP monotherapy is one of the first-choices for management of dogs with mild to moderate congestive heart failure caused from MI. Besides, in dogs with signs of more severe heart failure like as NYHA class IV, concomitant use of ACE inhibitor, diuretic, digoxin and other vascular dilators must be considered, because it has been considered that an ACE inhibitor showed higher efficacy combined with these drugs in human patients with hypertension and heart failure [1, 14] . However, combined use of an ACE inhibitor and a diuretic have potential adverse reactions [6, 7] . A trial of BP in combination with diuretics and/or cardionics is needed in dogs with more severe heart failure.
angiotensin inhibitors in hypertension and congestive heart failure. 
